安罗替尼治疗晚期肝癌患者的效果  

Anlotinib in the Treatment of Patients with Advanced Liver Cancer

作　　者：厉锋[1] 鲍乐[2] 丁轶人 赵鸿鹰 李文广[1] 袁磊[2] LI Feng;BAO Le;DING Yi-ren;ZHAO Hong-ying;LI Wen-guang;YUAN Lei(Department of Oncology,Xuzhou Cancer Hospital,Xuzhou 221000,Jiangsu,China;Department of Intervention,Xuzhou Cancer Hospital,Xuzhou 221000,Jiangsu,China;Department of Surgery,Xuzhou Cancer Hospital,Xuzhou 221000,Jiangsu,China)

机构地区：[1]徐州市肿瘤医院肿瘤内科,江苏徐州221000 [2]徐州市肿瘤医院肿瘤内科介入科,江苏徐州221000 [3]徐州市肿瘤医院肿瘤内科外科,江苏徐州221000

出　　处：《医学信息》2020年第18期138-140,共3页Journal of Medical Information

摘　　要：目的观察安罗替尼治疗晚期肝癌患者的临床效果及安全性。方法回顾性分析2019年2月~2020年3月在我院诊治的50例晚期肝癌患者临床资料,采用随机数字表法将其分为对照组(n=26)和研究组(n=24)。对照组采用索拉非尼治疗,研究组采用安罗替尼治疗,比较两组临床治疗总有效率、病情控制率、肝功能指标[丙氨酸氨基转移酶(ALT)、白蛋白(ALB)、总胆红素(TBIL)]、血清血管内皮生长因子(VEGF)水平、不良反应发生情况以及中位生存时间。结果研究组病情控制率为29.17%、总有效率为75.00%,与对照组的34.62%、73.08%比较,差异无有统计学意义(P>0.05);治疗后,两组ALT、ALB均低于治疗前,差异有统计学意义(P<0.05),TBIL与治疗前比较,差异无统计学意义(P>0.05);研究组ALT、ALB、TBIL与对照组比较,差异无统计学意义(P>0.05);研究组手足综合征、蛋白尿、高血压、腹泻、乏力、皮疹、脱发不良反应发生率均低于对照组,差异有统计学意义(P<0.05);随访3个月,研究组中位生存时间为(26.11±1.38)个月,长于对照组的(22.40±2.27)个月,差异有统计学意义(P<0.05)。结论安罗替尼治疗晚期肝癌效果确切,总有效率和疾病控制率与索拉非尼基本一致,但是安罗替尼不良反应少,可提高患者耐受性,促进治疗顺利进行,进一步延长患者生存时间。Objective To observe the clinical effect and safety of Anlotinib in the treatment of patients with advanced liver cancer.Methods The clinical data of 50 patients with advanced liver cancer diagnosed and treated in our hospital from February 2019 to March 2020 were retrospectively analyzed,and they were divided into a control group(n=26)and a study group(n=24)using a random number table method.The control group was treated with sorafenib and the study group was treated with anlotinib.The total effective rate,disease control rate,liver function indexes of the two groups were compared between the two groups.[Alanine aminotransferase(ALT),albumin(ALB),Total bilirubin(TBIL)],serum vascular endothelial growth factor(VEGF)levels,occurrence of adverse reactions,and median survival time.Results The disease control rate of the study group was 29.17%and the total effective rate was 75.00.Compared with 34.62%and 73.08%of the control group,the difference was not statistically significant(P>0.05);after treatment,the ALT and ALB of the two groups were both low before treatment,the difference was statistically significant(P<0.05).There was no statistically significant difference between TBIL and before treatment(P>0.05);There was no significant difference in ALT,ALB,TBIL between the study group and the control group(P>0.05);the incidence of adverse reactions such as hand-foot syndrome,proteinuria,hypertension,diarrhea,fatigue,rash,and alopecia in the study group were lower than those of the control group Group,the difference was statistically significant(P<0.05);follow-up for 3 months,the median survival time of the study group was(26.11±1.38)months,longer than the control group(22.40±2.27)months,the difference was statistically significant(P<0.05).Conclusion Anlotinib had a definite effect in the treatment of advanced liver cancer.The total effective rate and disease control rate were basically the same as those of sorafenib.However,there were few adverse reactions of Anlotinib,which could improve patient tolerance,promote sm

关 键 词：安罗替尼 晚期肝癌 病情控制率 

分 类 号：R735.7[医药卫生—肿瘤]